<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308247">
  <stage>Registered</stage>
  <submitdate>19/07/2009</submitdate>
  <approvaldate>21/07/2009</approvaldate>
  <actrnumber>ACTRN12609000602224</actrnumber>
  <trial_identification>
    <studytitle>Erythropoietin plus methylprednisolone versus methylprednisolone plus placebo in the treatment of acute spinal cord injury: A pilot study</studytitle>
    <scientifictitle>A randomized clinical trial on comparison of erythropoietin plus methylprednisolone versus methylprednisolone plus placebo in the improvement of neurologic outcome after acute spinal cord injury</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Acute spinal cord injury</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Methylprednisolone sodium succinate intravenously 30 mg/kg on admission and 5.4 mg/kg every hour till 23 hours(if admitted within 3 hours after injury) and till 47 hours (if admitted between 3-6 hours after injury) plus intravenous injection of 500 unit/kg of recombinant human erythropoietin in 500 ml normal saline on admission and another 500 unit/kg of recombinant human erythropoietin in 500 ml normal saline 24 hours later</interventions>
    <comparator>Methylprednisolone sodium succinate intravenously 30 mg/kg on admission and 5.4 mg/kg every hour till 23 hours(if admitted within 3 hours after injury) and till 47 hours (if admitted between 3-6 hours after injury) plus intravenous injection of  500 ml of normal saline on admission and another 500 ml of normal saline 24 hours later</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Neurologic examination for determination of American Spinal Injury Association (ASIA) scale</outcome>
      <timepoint>on admission,24 and 48 hours, one week, one and six months later</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rectal sphincter tone presence evaluated by rectal examination</outcome>
      <timepoint>on admission and one month later</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Spinal cord injury presenting to emergency department within 6 hours after injury</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>only qauda equina or nerve root involvement</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered container</concealment>
    <sequence>drawing numbered cards</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Fars</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Shiraz University of Medical Sciences</primarysponsorname>
    <primarysponsoraddress>Zand Blvd.
71345-1978
Shiraz</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pooyesh Darou</fundingname>
      <fundingaddress>No. 37, 5th Avenue
Fatemi Street
Tehran</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Pooyesh Darou</sponsorname>
      <sponsoraddress>No. 37, 5th Avenue
Fatemi Street
Tehran</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aimed to evaluate the effectiveness of intravenous human recombinnant erythropoietin plus methylprednisolone versus methylprednisolone alone to improve neurologic outcome during a six month follow-up after traumatic cord injury</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Shiraz University of Medical Sciences ethics committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Farid Zand</name>
      <address>Department of Anesthesiology
Nemazee Hospital
Nemazee Square
71937-11351</address>
      <phone>+98-711-233-7636</phone>
      <fax>+98-711-231-8072</fax>
      <email>zandf@sums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Farid Zand</name>
      <address>Department of Anesthesiology
Nemazee Hospital
Nemazee Square
71937-11351</address>
      <phone>+98-711-233-7636</phone>
      <fax>+98-711-231-8072</fax>
      <email>zandf@sums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Farid Zand</name>
      <address>Department of Anesthesiology
Nemazee Hospital
Nemazee Square
71937-11351</address>
      <phone>+98-711-233-7636</phone>
      <fax>+98-711-231-8072</fax>
      <email>zandf@sums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>